Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis
- PMID: 34045100
- DOI: 10.1016/j.vaccine.2021.04.068
Protective role of PhtD and its amino and carboxyl fragments against pneumococcal sepsis
Abstract
The implementation of polysaccharide-based vaccines has massively reduced the incidence of invasive pneumococcal diseases. However, there is great concern regarding serotype replacement and the increase in antibiotic resistant strains expressing non-vaccine capsular types. In addition, conjugate vaccines have high production costs, a limiting factor for their implementation in mass immunization programs in developing countries. These limitations have prompted the development of novel vaccine strategies for prevention of Streptococcus pneumoniae infections. The use of conserved pneumococcal antigens such as recombinant proteins or protein fragments presents an interesting serotype-independent alternative. Pht is a family of surface-exposed proteins which have been evaluated as potential vaccine candidates with encouraging results. The present work investigated the immune responses elicited by subcutaneous immunization of mice with the polyhistidine triad protein D (PhtD) and its amino and carboxyl terminal fragments. The proteins were immunogenic and protective against pneumococcal sepsis in mice. Antibodies raised against PhtD increased complement C3b deposition on the pneumococcal surface, mainly mediated by the alternative pathway. Sera from mice immunized with PhtD and PhtD_Cter promoted an increase in bacterial uptake by mouse phagocytes. The interaction of PhtD with the complement system regulator factor H was investigated in silico and in vitro by ELISA and western blot, confirming PhtD as a factor-H binding protein. Our results support the inclusion of PhtD and more specifically, its C-terminal fragment in a multicomponent serotype independent vaccine and suggests a role for the complement system in PhtD-mediated protection.
Keywords: Complement system, factor H; Invasive disease; PhtD; Pneumococcal vaccine; Streptococcus pneumoniae.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Immunization with PhtD truncated fragments reduces nasopharyngeal colonization by Streptococcus pneumoniae.Vaccine. 2020 May 27;38(26):4146-4153. doi: 10.1016/j.vaccine.2020.04.050. Epub 2020 Apr 30. Vaccine. 2020. PMID: 32362528
-
Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.Hum Vaccin Immunother. 2015;11(7):1836-9. doi: 10.1080/21645515.2015.1039210. Hum Vaccin Immunother. 2015. PMID: 25912273 Free PMC article.
-
Development of a bivalent protein-based vaccine candidate against invasive pneumococcal diseases based on novel pneumococcal surface protein A in combination with pneumococcal histidine triad protein D.Front Immunol. 2023 Aug 23;14:1187773. doi: 10.3389/fimmu.2023.1187773. eCollection 2023. Front Immunol. 2023. PMID: 37680628 Free PMC article.
-
Pneumococcal conjugate vaccine for young children.Manag Care. 2000 Sep;9(9):49-52, 54, 56-7 passim. Manag Care. 2000. PMID: 11116663 Review.
-
Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection.Paediatr Drugs. 2002;4(9):609-30. doi: 10.2165/00128072-200204090-00005. Paediatr Drugs. 2002. PMID: 12175274 Review.
Cited by
-
Pneumococcal Surface Proteins as Virulence Factors, Immunogens, and Conserved Vaccine Targets.Front Cell Infect Microbiol. 2022 May 12;12:832254. doi: 10.3389/fcimb.2022.832254. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35646747 Free PMC article. Review.
-
Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?Hum Vaccin Immunother. 2025 Dec;21(1):2461844. doi: 10.1080/21645515.2025.2461844. Epub 2025 Feb 25. Hum Vaccin Immunother. 2025. PMID: 39999432 Free PMC article. Review.
-
A fusion protein comprising pneumococcal surface protein A and a pneumolysin derivate confers protection in a murine model of pneumococcal pneumonia.PLoS One. 2022 Dec 7;17(12):e0277304. doi: 10.1371/journal.pone.0277304. eCollection 2022. PLoS One. 2022. PMID: 36477013 Free PMC article.
-
Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies.Front Cell Infect Microbiol. 2022 Jan 28;12:824788. doi: 10.3389/fcimb.2022.824788. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35155281 Free PMC article. Review.
-
Streptococcus pneumoniae interactions with the complement system.Front Cell Infect Microbiol. 2022 Jul 28;12:929483. doi: 10.3389/fcimb.2022.929483. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35967850 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical